Lexicon Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Global Alliance for Tb Drug Development

Cumbre IP Ventures, L.p.

Jiancheng Wang

Zhenkun Ma

Genliang Lu

Cynthia Anne Fink

Charles Z Ding

Keith D Combrink

Li Dong

John E Macor

William Alexander Denny

Joanne J Bronson

Kenneth Gordon Carson

Yulian Zhang

Carolyn Diane Dzierba

Yingzhi Bi

Michael Alan Green

Giovanni Cianchetta

Brian Desmond Palmer

Joseph Barbosa

Andrew Mark Thompson

Yafei Jin

In Ho Kim

Adrian Blaser

David Kimball

Soojin Kwon

Greg Zipp

Hamish Scott Sutherland

Iveta Kmentova

G Gregory Zipp

Minsoo Song

Dianjun D Chen

A Simon Lynch

Michael Green

Andrew M Thompson

Diajun D Chen

Cynthia Ann Fink

This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.

Multicyclic compounds and methods of their use

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.

Modulators of G protein-coupled receptor 88

Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.

Nitroheteroaryl-containing rifamycin derivatives

The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as

Bicyclic nitroimidazole-substituted phenyl oxazolidinones

Growing community of inventors

Revere, MA, United States of America

Jiancheng Wang